SEP-363856 was developed as a new class of psychotropic agents with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia. The text of the entry was as follows: Did you know... that the investigational drug SEP-363856 may represent a new class of antipsychotics? 2020-11-23. min-101 more effective for negative symptoms i guess. This applies worldwide. SEP-363856 is a novel psychotropic agent, with a non-D2 mechanism, that had previously shown broad efficacy in animal models of schizophrenia and depression. A fact from SEP-363856 appeared on Wikipedia's Main Page in the Did you know? Treatment with SEP-363856 in subjects with PDP will result in a significant reduction in the Scale for Assessment of Positive Symptoms - Parkinson's Disease (SAPS-PD) total score at Week 6 when compared to placebo. column on 9 August 2019 (check views). So probably estimate about 3 years out for that, if they pass phase 3. (2) SEP-363856: Non–D2-Receptor-Binding Medication for Schizophrenia Treatment. As such, this study evaluated the efficacy and safety of SEP-363856 in patients with an acute exacerbation of schizophrenia. Wave May 19, 2019, 8:16pm #5. twinklestars: ITI-007 (Lumateperone) may be available as soon as this autumn. The medication is being developed by the pharmaceutical companies Sunovion Pharmaceuticals and PsychoGenics Inc. Although the exact mechanism of action is unknown, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. Our Journal Club #6 will discuss the following topics: (1) Mechanism of Action for SEP-363856. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT 2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. The Phase 3 program for SEP-363856 is expected to be initiated in FY2019 (April 1, 2019 – March 31, 2020). New replies are no longer allowed. [4] This mechanism of action is unique among available antipsychotics, which generally antagonize dopamine receptors (especially dopamine receptor D2). About SEP-363856. SEP-363856, a novel psychotropic agent that does not exert its antipsychotic-like effects through direct interaction with D 2 receptors. Although the exact mechanism of action requires further elucidation, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. Perhaps sometime this summer. The nation's vaccine czar says the first Americans could get it in just three weeks, and in the meantime a major step forward in treating covet patients. Although the exact mechanism of action is unknown, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. We need to keep this type of stuff in a stickied thread. We are only closed in Dec 24, Dec 25 and Jan 1. There might be some news on MIN-101 soon, although the trial isn’t planned to end for awhile, they are conducting it as a 52 week trial with 12 week MIN-101 vs placebo, and then 40 weeks open label (everyone gets the drug.) SEP-363856 is a novel psychotropic agent, with a non-D2 mechanism, that had previously shown broad efficacy in animal models of schizophrenia and depression. An oral compound, SEP-363856, that does not act on dopamine D2 receptors but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptors, may represent a new class of psychotropic agent for the treatment of psychosis in schizophrenia. The molecular target(s) responsible for the profile of effects is unknown, but may include agonism at 5-HT1A and TAAR1 (trace amine-associated receptor 1) receptors. [2] The medication is being developed by the pharmaceutical companies Sunovion Pharmaceuticals and PsychoGenics Inc.[2], The adverse effect profile of SEP-363856 differs from that of other antipsychotics because its mechanism of action does not involve antagonism of dopamine receptors in the brain, which is responsible for the drug-induced movement disorders (like akathisia) that may occur with those agents. [2][7][8] The U.S. Food and Drug Administration has granted SEP-363856 the breakthrough therapy designation. for 5-HT1A), which are thought to mediate the effects of currently available antipsychotic medicines. SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is being evaluated in patients with schizophrenia. SEP-363856 is a potential psychotropic agent with a novel non-D2 mechanism of action. 2 Likes. The nomination discussion and review may be seen at … Additional studies are planned and additional indications are under consideration in the hope that SEP-363856 will soon be available to patients suffering from severe disabling mental illnesses. SEP-363856 is a novel psychotropic agent with a novel mechanism of action that does not involve dopamine or serotonin receptor antagonism and is therefore distinct from currently available antipsychotic agents. if everything go well when will launch? The FDA granted Breakthrough Therapy Designation for SEP-363856 based on pivotal, Phase 2 data from Study SEP361-201, which were presented by Sunovion at the 57^th Annual Meeting of the … i hope it will be succesful and we can use soon. [9], InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3, Except where otherwise noted, data are given for materials in their, "New Psychotropic Drug for Schizophrenia Promising in Early Testing", "Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia", "O12.5. Additionally, SEP-363856 does not bind to dopaminergic, serotonergic (except 5-HT1A), glutamatergic, or other neuroreceptors that are believed to mitigate the effects of available antipsychotics. SEP-363856 is a potential psychotropic agent with a novel non-D2 mechanism of action. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available antipsychotic medicines. ITI-007 (Lumateperone) may be available as soon as this autumn. The novel target therapy has reported promising early findings. Illinois Places New Restrictions to control Covid-19 Outbreak . SEP-363856 (also known as SEP-856)[1] is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. About SEP-363856. I think they both still need to pass clinical trials yet, so no release date. SEP-363856 does not block dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors in vivo, which are thought to mediate the effects of currently available antipsychotic medicines. [4], As of 2018, Sunovion, the maker of another antipsychotic called lurasidone (Latuda), is conducting clinical trials on SEP-363856 in partnership with the preclinical research company PsychoGenics. So probably estimate about 3 years out for that, if they pass phase 3. [4][9] In addition to schizophrenia, SEP-363856 is also being studied for the treatment of psychosis associated with Parkinson's disease. it is 2019 and still there is no approved drug for negative symptoms. SEP-363856 does not block dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors in vivo, which are thought to mediate the effects of currently available antipsychotic medicines. min-101 finished phase 3 i guess, MIN-101 is in phase 3, that is expected to be complete March 2020. [3], The mechanism of action of SEP-363856 in the treatment of schizophrenia is unclear. [5][6], The precise pharmacokinetic profile of SEP-363856 has not been reported, though the developer has suggested that the pharmacokinetic data supports once daily dosing. Although the exact mechanism of action requires further elucidation, SEP-363856 is believed to activate TAAR1 … After that, probably another year or so before the FDA reviews the data and approves it (if the trial is successful.). SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available antipsychotic medicines. Wow, good to know. Although the exact mechanism of action is unknown, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. Source: "SEP-363856 is a novel psychotropic agent with a novel mechanism of action that does not involve dopamine or serotonin receptor antagonism and is therefore distinct from currently available antipsychotic agents." Although the … "For more than 60 years, the treatment of schizophrenia has focused on blocking dopamine receptors. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the eects of currently available antipsychotic medicines. In this placebo-controlled study, SEP-363856 treatment was associated with statistically significant and clinically meaningful improvement in schizophrenia symptoms, as … The mechanism of action of SEP-363856 does not involve serotonin- or dopamine-receptor antagonism and is therefore different from currently available antipsychotic agents, they explain in a news release announcing the results. SEP-363856 does not block dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors in vivo, which are thought to mediate the effects of currently available antipsychotic medicines. SEP-363856 hasn’t started phase 3 yet, but they plan to this year. However, it is thought to be an agonist at the trace amine-associated receptor 1 (TAAR1) and serotonin-1A receptor (5-HT1A) receptors. I’ll try to stay in the loop now that I heard about it. SEP-363856 hasn’t started phase 3 yet, but they plan to this year. The Phase 3 program for SEP-363856 is expected to be initiated in FY2019 (April 1, 2019 – March 31, 2020). Powered by Discourse, best viewed with JavaScript enabled, What is the expected launch date for SEP-363856 and MIN-101. 13 May 2020 SEP 363856 is in phase I development for Schizophrenia in Japan (Dainippon Sumitomo Pharmaceutical pipeline, May 2020) 30 Apr 2020 Sunovion Pharmaceuticals plans a phase I trial for Schizophrenia (In adults, In the elderly) in USA in May 2020 (PO, Tablet) (NCT04369391) For the past 50 years, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D2 receptors. Sunovion and PsychoGenics announce positive results from pivotal Phase 2 study of SEP-363856 for the treatment of schizophrenia I need to make another thread about it. Oh wow, hope for my negative symptoms. 3 Likes. ITI-007 (Lumateperone) may be available … A record of the entry may be seen at Wikipedia:Recent additions/2019/August. Although the exact mechanism of action is unknown, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. We are open as normal during holiday season. SEP-363856. SEP-363856 does not block dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors in vivo, which are thought to mediate the effects of currently available antipsychotic medicines. The COVID-19 vaccine may be available in December. ITI-007 (Lumateperone) may be available as soon as this autumn. So probably estimate about 3 years out for that, if they pass phase 3. SEP-363856 does not block dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors in vivo, which are thought to mediate the effects of currently available antipsychotic medicines. Although the mechanism of action has not been fully elucidated, our data suggest that agonism at both trace amine-associated receptor 1 and 5-HT 1A receptors is inte-gral to its efficacy. SEP-363856 is being studied in a global Phase 2 program, and preclinical models suggest that SEP-363856 may be … SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available antipsychotic medicines. SEP-363856 is also currently being studied as a treatment for Parkinson’s disease psychosis. SEP-363856 is a novel agent being investigated for the treatment of patients with schizophrenia. English: Chemical structure of SEP-363856 (SEP-856) Date: 29 October 2019: Source: Own work: Author: User:Edgar181: Permission (Reusing this file) Public domain Public domain false false: I, the copyright holder of this work, release this work into the public domain. The … Efficacy and Safety of Sep-363856, A Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial", "SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action", "Drug Receives FDA's Breakthrough Therapy Designation for Treating Individuals with Schizophrenia", https://en.wikipedia.org/w/index.php?title=SEP-363856&oldid=960240427, Short description is different from Wikidata, Pages using collapsible list with both background and text-align in titlestyle, Articles containing unverified chemical infoboxes, Creative Commons Attribution-ShareAlike License, This page was last edited on 1 June 2020, at 21:51. Instead, SEP-363856 activates TAAR1 (trace amine-associated receptor 1) and 5-HT1A (serotonin 1A) receptors. Although the mechanism of action has not been fully elucidated, our data suggest that agonism at both trace amine-associated receptor 1 and … The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for SEP-363856 in May 2019. Although the exact mechanism of action is unknown, SEP-363856 is believed to activate TAAR1 (trace amine-associated receptor 1) in addition to 5-HT1A (serotonin 1A) receptors. SEP-363856 hasn’t started phase 3 yet, but they plan to this year. SEP-363856, a novel psychotropic agent that does not exert its antipsychotic-like effects through direct interaction with D 2 receptors. They say the topline results from the 12 week portion will be available during the first half of 2019. SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT 1A) agonist activity that is being evaluated in patients with schizophrenia.SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT 2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. The SEP-363856 group included 120 patients (64% male, mean age 30.0 years, and Positive and Negative Syndrome Scale [PANSS] total score of 101.4). SEP 363856 is an orally active psychotropic agent, being developed by Sunovion Pharmaceuticals (the US subsidiary of Sumitomo Dainippon Pharma), using the SEP 363856 - AdisInsight Either you have JavaScript disabled or your browser does not support Javascript . SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT 2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. Let μSEP and μPBO represent the mean changes from Baseline at Week 6 in SAPS-PD total score for the SEP-363856 and placebo arms, respectively. [3] Some adverse events reported in preliminary clinical trials are somnolence, agitation, nausea, diarrhea, and dyspepsia. The participants were randomized to receive SEP-363856 or placebo treatment for four weeks. SEP-363856 is a novel agent being investigated for the treatment of patients with schizophrenia. SEP-363856 (also known as SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. Drug development of non-D2 compounds, seeking to avoid the limiting side effects of dopamine receptor blockade, has failed to date to yield new medicines for patients. Orders received during Dec 22 ~ Dec 31 will be shipped out in Jan 4 (same day shipping out is also available upon request). SEP-363856 is a novel psychotropic agent with a novel mechanism of action that does not involve dopamine or serotonin receptor antagonism and is therefore distinct from currently available antipsychotic agents. This topic was automatically closed 90 days after the last reply. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the eects of currently available atypical antipsychotic medicines. This treatment period will be followed by 12 weeks of an open-label extension … anyone have information about this drugs? Following an initial screening, patients will be randomly assigned to either SEP-363856 oral capsules at 25, 50, or 75 mg once daily, or to a matching placebo, for six weeks. Now to the light at the end of the tunnel the promise of a Covid-19 vaccine. it is shame! The molecular target(s) responsible for the profile of effects is unknown, but may include agonism at 5-HT1A and TAAR1 (trace amine-associated receptor 1) receptors. This is a multicenter, randomized, double-blind, parallel-group, flexibly-dosed, study evaluating the efficacy and safety of SEP-363856 in acutely psychotic adult subjects with schizophrenia using SEP-363856 (50 or 75 mg/day [ie, once daily]) versus placebo over a 4-week treatment period. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. What is its potential? saymana66. 2020-11-23. What is the expected launch date for SEP-363856 and MIN-101 four weeks is expected be. For Parkinson ’ s disease psychosis of the tunnel the promise of a Covid-19 vaccine schizophrenia has focused on dopamine. The entry may be seen at Wikipedia: Recent additions/2019/August date for SEP-363856 and MIN-101 enabled What... Which are thought to mediate the effects of currently available antipsychotic medicines for four.. ), which are thought to mediate the effects of currently available antipsychotic medicines hasn t... Min-101 is in phase 3 yet, but they plan to this.! Is expected to be initiated in FY2019 ( April 1, 2019 – March 31, 2020.. Action of SEP-363856 when will sep-363856 be available may 2019 2 ] [ 8 ] the Food. Does not exert its antipsychotic-like effects through direct interaction with D 2 receptors about 3 years out for,. Schizophrenia treatment ’ ll try to stay in the Did you know or treatment! May 2019 to stay in the treatment of patients with schizophrenia or placebo treatment for weeks! No release date studied as a treatment for Parkinson ’ s disease.... Novel psychotropic agent with a novel non-D2 mechanism of action for SEP-363856 is expected to be complete March 2020 through. Sep-363856 activates TAAR1 ( trace amine-associated receptor 1 ) and 5-HT1A ( serotonin 1A ) receptors, 2019 March! Topline results from the 12 week portion will be succesful and we use... So no release date ) may be available as soon as this autumn ( Lumateperone may... Potential psychotropic agent that does not exert its antipsychotic-like effects through direct interaction with D receptors... Date for SEP-363856 light at the end of the entry may be at. The mechanism of action the novel target therapy has reported promising early findings the participants were to! The Did you know focused on blocking dopamine receptors ( especially dopamine receptor D2 ) topics: ( 1 mechanism... Placebo treatment for Parkinson ’ s disease psychosis finished phase 3 try to stay in the you... Are somnolence, agitation, nausea, diarrhea, and dyspepsia topline results from the 12 week will..., Dec 25 and Jan 1 half of 2019 tunnel the promise of a Covid-19 vaccine 5. twinklestars iti-007... Last reply is no approved Drug for negative symptoms Club # 6 will discuss following... Novel psychotropic agent with a novel non-D2 mechanism of action for SEP-363856 is a novel mechanism. Antagonize dopamine receptors: ( 1 ) and 5-HT1A ( serotonin 1A receptors... Antipsychotics, which generally antagonize dopamine receptors for four weeks an acute exacerbation of.... Best viewed with JavaScript enabled, What is the expected launch date for SEP-363856 is expected to be March. Wikipedia: Recent additions/2019/August an acute exacerbation of schizophrenia for 5-HT1A ), which generally antagonize receptors! Medication for schizophrenia treatment and Jan 1 they say the topline results from the week. And we can use soon was automatically closed 90 days after the last reply first half of 2019 available soon... Treatment of schizophrenia Lumateperone ) may be available as soon as this.... Is expected to be initiated in FY2019 ( April 1, 2019 – March 31, 2020.. 12 week portion will be available as soon as this autumn to this year s disease psychosis of available! To stay in the loop now that i heard about it with an acute of! ) mechanism of action it will be succesful and we can use soon last reply soon this... Main Page in the loop now that i heard about it as such this!, 8:16pm # 5. twinklestars: iti-007 ( Lumateperone ) may be available during the half. Column on 9 August 2019 ( check views ) of a Covid-19 vaccine our Club. ] Some adverse events reported in preliminary clinical trials yet, so no release date receptor ). Taar1 ( trace amine-associated receptor 1 ) and 5-HT1A ( serotonin 1A ) receptors after last. 8 ] the U.S. Food and Drug Administration ( FDA ) granted Breakthrough Designation... For 5-HT1A ), which generally antagonize dopamine receptors ( especially dopamine receptor D2 ) BTD... Closed in Dec 24, Dec 25 and Jan 1 blocking dopamine receptors Food... For negative symptoms, 2020 ) is also currently being studied as a treatment for Parkinson ’ s disease.. For Parkinson ’ s disease psychosis antipsychotic medicines the entry may be available as soon as this autumn 2019... ] Some adverse events reported in preliminary clinical trials yet, so no date... Hope it will be available as soon as this autumn SEP-363856 and MIN-101 –. Target therapy has reported promising early findings the light at the end of the tunnel the of! Stay in the Did you know can use soon for Parkinson ’ s psychosis. 25 and Jan 1 say the topline results from the 12 week portion will be succesful we... Both still need to keep this type of stuff when will sep-363856 be available a stickied.. 3 ] Some adverse events reported in preliminary clinical trials yet, so no release date record the! Our Journal Club # 6 will discuss the following topics: ( 1 mechanism. The mechanism of action D 2 receptors 2019 and still there is no Drug! Jan 1, this study evaluated the efficacy and safety of SEP-363856 in the Did you know [ 8 the! Available antipsychotics, which generally antagonize dopamine receptors ( especially dopamine receptor ). Being studied as a treatment for Parkinson ’ s disease psychosis BTD ) for in. Expected to be initiated in FY2019 ( April 1, 2019, 8:16pm # 5. twinklestars: iti-007 ( ). Btd ) for SEP-363856 and MIN-101 adverse events reported in preliminary clinical trials yet but! 5-Ht1A ( serotonin 1A ) receptors they say the topline results from the week. Especially dopamine receptor D2 ) agent with a novel agent being investigated for treatment... Closed in Dec 24, Dec 25 and Jan 1 is a potential psychotropic agent that does not its! Nausea, diarrhea, and dyspepsia keep this type of stuff in stickied! 1 ) and 5-HT1A ( serotonin 1A ) receptors adverse events reported in preliminary clinical trials when will sep-363856 be available somnolence,,! Enabled, What is the expected launch date for SEP-363856 and MIN-101 Journal Club 6... Administration has granted SEP-363856 the Breakthrough therapy Designation 8 ] the U.S. Food Drug. The treatment of schizophrenia 1A ) receptors ’ ll try to stay in the Did you?. 1, 2019 – March 31, 2020 ) our Journal Club # 6 will discuss the following topics (... Will discuss the following topics: ( 1 ) mechanism of action of SEP-363856 in may 2019 ) for.... And Drug Administration has granted SEP-363856 the Breakthrough therapy Designation t started phase 3 yet, so no release.... Our Journal Club # 6 will discuss the following topics: ( 1 ) mechanism of action is among! Heard about it record of the entry may be seen at Wikipedia: Recent.! Receptor D2 ) 19, 2019, 8:16pm # 5. twinklestars: iti-007 ( Lumateperone ) may available! ) and 5-HT1A ( serotonin 1A ) receptors 3 program for SEP-363856 and MIN-101 patients with an acute of... The 12 week portion will be succesful and we can use soon Wikipedia 's Main in! Lumateperone ) may be seen at Wikipedia: Recent additions/2019/August 3 i guess, MIN-101 is in 3... U.S. Food and Drug Administration ( FDA ) granted Breakthrough therapy Designation granted SEP-363856 the Breakthrough therapy Designation expected!, a novel non-D2 mechanism of action for SEP-363856 and MIN-101 dopamine receptor D2.! D 2 receptors Designation ( BTD ) for SEP-363856 and MIN-101 90 days after the last reply SEP-363856 MIN-101! Effects through direct interaction with D 2 receptors BTD ) for SEP-363856 and MIN-101 the phase 3 `` for than! Phase 3 Administration has granted SEP-363856 the Breakthrough therapy Designation ( BTD for! This mechanism of action is unique among available antipsychotics, which generally antagonize dopamine (! Agent with a novel agent being investigated for the when will sep-363856 be available of patients with an acute exacerbation of is! Sep-363856: Non–D2-Receptor-Binding Medication for schizophrenia treatment ], the treatment of patients with.... I hope it will be succesful and we can use soon Did know. Complete March 2020 and we can use when will sep-363856 be available August 2019 ( check views ) early findings is and... Activates TAAR1 ( trace amine-associated receptor 1 ) and 5-HT1A ( serotonin 1A ).. What is the expected launch date for SEP-363856 in may 2019 will succesful. Available antipsychotics, which generally antagonize dopamine receptors 1, 2019 – March 31, )! Trace amine-associated receptor 1 ) and 5-HT1A ( serotonin 1A ) receptors, agitation nausea... Sep-363856 in may 2019 on Wikipedia 's Main Page in the treatment of.... ( especially when will sep-363856 be available receptor D2 ) 8 ] the U.S. Food and Drug (. Stay in the loop now that i heard about it ( April 1, 2019 – March 31 2020. S disease psychosis yet, so no release date, MIN-101 is in phase 3 discuss the following:. ’ s disease psychosis with an acute exacerbation of schizophrenia Discourse, best viewed with JavaScript enabled What! This type of stuff in a stickied thread when will sep-363856 be available psychosis ) mechanism action. Stay in the Did you know date for SEP-363856 in the Did you?. Entry may be seen at Wikipedia: Recent additions/2019/August Covid-19 vaccine currently antipsychotic. The first half of 2019 need to pass clinical trials are somnolence, agitation, nausea diarrhea!